Skip to main content
Equibles
CABA logo

CABA · Cabaletta Bio, Inc. · Documents

Track CABA — free

Use CABA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CABA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.33 -0.12 (-8.28%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Nov 5, 2026

The latest filing states the doubt was alleviated.

“As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we had previously identified conditions that raised substantial doubt about our ability to continue as a going concern. During the quarter ended September 30, 2026, we raised additional funds through the exercise of common stock warrants for proceeds of $115.0 million and sold 1.9 million shares pursuant to the 2025 ATM Program for net proceeds of $6.0 million. As a result of these cash raises, the conditions that previously raised substantial doubt are no longer present.”
View the 10-Q filed Nov 5, 2026
Market Cap
$286.91M
Shares
215.72M
Volume · Nov 12 3.73M Avg daily vol (3M) 5.32M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $167.86M 10-K filed Mar 23, 2026 Quarterly report FY2026 Q3 Net loss $53.05M 10-Q filed Nov 5, 2026 Latest results Financial results 8-K filed Nov 5, 2026
2026
Nov 9
Current report 8-K
Rese-cel shows durable responses across three autoimmune diseases

Cabaletta Bio, Inc. reported new Phase 1/2 rese-cel data: 100% (6/6) dermatomyositis patients sustained moderate-to-major responses through one year, 100% (5/5) biopsied lupus nephritis patients achieved DORIS remission, and 71% (5/7) systemic sclerosis patients achieved rCRISS-50.

Regulation FD disclosure, Other events Read from the first part of this long document
4 source passages
Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new Phase 1/2 clinical data on resecabtagene autoleucel (rese-cel) to be presented in one oral and two poster presentations at the American College of Rheumatology (ACR) Convergence 2026 annual meeting in Orlando, FL. 100% (6/6) of patients maintained an immunomodulator-free, moderate-to-major Total Improvement Score (TIS) response through one year, with 83% (5/6) achieving that level as early as Week 16, the timepoint corresponding to the primary endpoint of the ongoing registrational dermatomyositis (DM) and antisynthetase syndrome (ASyS) cohort. 100% (5/5) of patients who underwent an optional repeat kidney biopsy after rese-cel infusion achieved the definition of remission in systemic lupus erythematosus (DORIS) off all immunomodulators and on no or low-dose steroids. 71% (5/7) of patients achieved rCRISS-50 at one year, with 86% (6/7) of patients achieving rCRISS-25 at the same timepoint. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Myositis topline targeted for second half of 2027

Cabaletta Bio expects registrational myositis topline results in the second half of 2027 to support a potential BLA submission in the first quarter of 2028. It held $299.4 million in cash and cash equivalents as of September 30, 2026.

Net loss $53.05M Diluted EPS -$0.28
Read from the MD&A section
2 source passages
We anticipate reporting registrational myositis topline results in the second half of 2027 to support a potential BLA submission in the first quarter of 2028. As of September 30, 2026, we had $299.4 million in cash and cash equivalents. Open the document at this passage
Sep 14
Current report 8-K
Other events AI summary on its way
May 4
Current report 8-K
Other events AI summary on its way
Apr 28
Proxy statement DEF 14A Meeting Jun 9, 2026
Proxy statement AI summary on its way
Apr 20
Current report 8-K
Other events AI summary on its way
Apr 17
Proxy statement PRE 14A Meeting Jun 9, 2026
Proxy statement AI summary on its way
Mar 23
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $167.86M Diluted EPS -$2.10
2025
2024
Showing 1–50 of 150 documents
Key facts CIK 1759138 CUSIP 12674W109 13F (30d) 80 filings 71 filers Visit website Investor relations